$GERN
GERON CORP

2024 Q4 Form 10-Q Financial Statement

#000095017024123282 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $28.27M
YoY Change 17138.41%
Cost Of Revenue $456.0K
YoY Change
Gross Profit $27.82M
YoY Change
Gross Profit Margin 98.39%
Selling, General & Admin $35.88M
YoY Change 95.51%
% of Gross Profit 128.98%
Research & Development $20.15M
YoY Change -31.51%
% of Gross Profit 72.45%
Depreciation & Amortization $31.00K
YoY Change -71.82%
% of Gross Profit 0.11%
Operating Expenses $56.49M
YoY Change 18.23%
Operating Profit -$28.22M
YoY Change -40.74%
Interest Expense $3.046M
YoY Change 47.43%
% of Operating Profit
Other Income/Expense, Net -$63.00K
YoY Change -31.52%
Pretax Income -$26.45M
YoY Change -40.98%
Income Tax
% Of Pretax Income
Net Earnings -$26.45M
YoY Change -40.97%
Net Earnings / Revenue -93.55%
Basic Earnings Per Share -$0.04
Diluted Earnings Per Share -$0.04
COMMON SHARES
Basic Shares Outstanding 604.5M 602.8M
Diluted Shares Outstanding 662.2M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $339.8M
YoY Change 8.37%
Cash & Equivalents $60.34M
Short-Term Investments $279.4M
Other Short-Term Assets $7.911M
YoY Change 16.34%
Inventory $20.28M
Prepaid Expenses
Receivables $28.01M
Other Receivables $2.082M
Total Short-Term Assets $398.1M
YoY Change 18.79%
LONG-TERM ASSETS
Property, Plant & Equipment $1.595M
YoY Change 29.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $37.31M
YoY Change -44.97%
Other Assets $4.931M
YoY Change -5.17%
Total Long-Term Assets $46.89M
YoY Change -39.83%
TOTAL ASSETS
Total Short-Term Assets $398.1M
Total Long-Term Assets $46.89M
Total Assets $445.0M
YoY Change 7.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.73M
YoY Change 0.37%
Accrued Expenses $36.49M
YoY Change -12.84%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $71.56M
YoY Change 224.4%
Total Short-Term Liabilities $137.9M
YoY Change 54.31%
LONG-TERM LIABILITIES
Long-Term Debt $12.28M
YoY Change -58.86%
Other Long-Term Liabilities $2.458M
YoY Change -23.19%
Total Long-Term Liabilities $12.28M
YoY Change -58.86%
TOTAL LIABILITIES
Total Short-Term Liabilities $137.9M
Total Long-Term Liabilities $12.28M
Total Liabilities $150.2M
YoY Change 25.99%
SHAREHOLDERS EQUITY
Retained Earnings -$1.747B
YoY Change 13.02%
Common Stock $2.038B
YoY Change 10.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $292.3M
YoY Change
Total Liabilities & Shareholders Equity $445.0M
YoY Change 7.73%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$26.45M
YoY Change -40.97%
Depreciation, Depletion And Amortization $31.00K
YoY Change -71.82%
Cash From Operating Activities -$58.94M
YoY Change 15.94%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$554.0K
YoY Change -87.77%
Cash From Investing Activities -$554.0K
YoY Change -88.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.578M
YoY Change -87.81%
NET CHANGE
Cash From Operating Activities -58.94M
Cash From Investing Activities -554.0K
Cash From Financing Activities 3.578M
Net Change In Cash -55.92M
YoY Change 113.43%
FREE CASH FLOW
Cash From Operating Activities -$58.94M
Capital Expenditures $0.00
Free Cash Flow -$58.94M
YoY Change 15.48%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0000886744
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-20859
dei Entity Registrant Name
EntityRegistrantName
GERON CORP
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
75-2287752
dei Entity Address Address Line1
EntityAddressAddressLine1
919 EAST HILLSDALE BOULEVARD
dei Entity Address Address Line2
EntityAddressAddressLine2
SUITE 250
dei Entity Address City Or Town
EntityAddressCityOrTown
FOSTER CITY
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94404
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
473-7700
dei Trading Symbol
TradingSymbol
GERN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
604501016
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
60344000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70023000
CY2024Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1854000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1115000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
279430000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
263676000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
28007000
CY2024Q3 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
2082000
CY2023Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
1655000
CY2024Q3 us-gaap Inventory Net
InventoryNet
20283000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6057000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4879000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
398057000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
341348000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
37312000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
43298000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1595000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1177000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3055000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3556000
CY2024Q3 gern Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
4931000
CY2023Q4 gern Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
4697000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
444950000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
394076000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
13734000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6161000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
15180000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
13759000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
968000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
949000
CY2024Q3 us-gaap Debt Current
DebtCurrent
71562000
CY2023Q4 us-gaap Debt Current
DebtCurrent
46893000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
36489000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
40308000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
137933000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
108070000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2458000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3006000
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
12275000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
35051000
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
603000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
545000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2037653000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1844988000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1746989000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1597769000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1017000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
185000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
292284000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
247949000
CY2024Q3 us-gaap Assets
Assets
444950000
CY2023Q4 us-gaap Assets
Assets
394076000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
28271000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
164000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
29457000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
214000
CY2024Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
456000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
473000
CY2024Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
20153000
CY2023Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
29426000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
80305000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
92135000
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
35877000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
18350000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
102361000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
47734000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
56486000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
47776000
us-gaap Operating Expenses
OperatingExpenses
183139000
us-gaap Operating Expenses
OperatingExpenses
139869000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-28215000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-47612000
us-gaap Operating Income Loss
OperatingIncomeLoss
-153682000
us-gaap Operating Income Loss
OperatingIncomeLoss
-139655000
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
4877000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
4965000
us-gaap Investment Income Interest
InvestmentIncomeInterest
14448000
us-gaap Investment Income Interest
InvestmentIncomeInterest
13556000
CY2024Q3 us-gaap Interest Expense
InterestExpense
3046000
CY2023Q3 us-gaap Interest Expense
InterestExpense
2066000
us-gaap Interest Expense
InterestExpense
9798000
us-gaap Interest Expense
InterestExpense
5991000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-63000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-92000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-188000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-64000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-26447000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-44805000
us-gaap Net Income Loss
NetIncomeLoss
-149220000
us-gaap Net Income Loss
NetIncomeLoss
-132154000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
662158182
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
662158182
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
579508305
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
579508305
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
639933612
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
639933612
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
562445577
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
562445577
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-26447000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-44805000
us-gaap Net Income Loss
NetIncomeLoss
-149220000
us-gaap Net Income Loss
NetIncomeLoss
-132154000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1507000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-11000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
816000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-722000
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
48000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
6000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
17000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-9000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24892000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-44810000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-148387000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-132885000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
247949000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-55390000
CY2024Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-448000
CY2024Q1 gern Adjustment To Accumulated Other Comprehensive Gain Loss Foreign Currency Translation Adjustment
AdjustmentToAccumulatedOtherComprehensiveGainLossForeignCurrencyTranslationAdjustment
-10000
CY2024Q1 gern Public Offering Stock Issued During Period Value New Issue
PublicOfferingStockIssuedDuringPeriodValueNewIssue
141000000
CY2024Q1 gern Issuance Of Common Stock In Connection With Warrant Exercise Value
IssuanceOfCommonStockInConnectionWithWarrantExerciseValue
49000
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
6749000
CY2024Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
92000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4877000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
344868000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-67383000
CY2024Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-243000
CY2024Q2 gern Adjustment To Accumulated Other Comprehensive Gain Loss Foreign Currency Translation Adjustment
AdjustmentToAccumulatedOtherComprehensiveGainLossForeignCurrencyTranslationAdjustment
-21000
CY2024Q2 gern Adjustment To Additional Paid In Capital Offering Expenses
AdjustmentToAdditionalPaidInCapitalOfferingExpenses
-271000
CY2024Q2 gern Issuance Of Common Stock In Connection With Warrant Exercise Value
IssuanceOfCommonStockInConnectionWithWarrantExerciseValue
365000
CY2024Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
16000
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
16373000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12625000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
366000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
306695000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-26447000
CY2024Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
1507000
CY2024Q3 gern Adjustment To Accumulated Other Comprehensive Gain Loss Foreign Currency Translation Adjustment
AdjustmentToAccumulatedOtherComprehensiveGainLossForeignCurrencyTranslationAdjustment
47000
CY2024Q3 gern Issuance Of Common Stock In Connection With Warrant Exercise Value
IssuanceOfCommonStockInConnectionWithWarrantExerciseValue
4000
CY2024Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
14000
CY2024Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3574000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6890000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
292284000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
79998000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-38122000
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
75000
CY2023Q1 gern Adjustment To Accumulated Other Comprehensive Gain Loss Foreign Currency Translation Adjustment
AdjustmentToAccumulatedOtherComprehensiveGainLossForeignCurrencyTranslationAdjustment
-16000
CY2023Q1 gern Public Offering Stock Issued During Period Value New Issue
PublicOfferingStockIssuedDuringPeriodValueNewIssue
213337000
CY2023Q1 gern Issuance Of Common Stock In Connection With Warrant Exercise Value
IssuanceOfCommonStockInConnectionWithWarrantExerciseValue
59835000
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
112000
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
7875000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2961000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
326055000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-49227000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-786000
CY2023Q2 gern Adjustment To Accumulated Other Comprehensive Gain Loss Foreign Currency Translation Adjustment
AdjustmentToAccumulatedOtherComprehensiveGainLossForeignCurrencyTranslationAdjustment
1000
CY2023Q2 gern Issuance Of Common Stock In Connection With Warrant Exercise Value
IssuanceOfCommonStockInConnectionWithWarrantExerciseValue
17767000
CY2023Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
99000
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
573000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3945000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
298427000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-44805000
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-11000
CY2023Q3 gern Adjustment To Accumulated Other Comprehensive Gain Loss Foreign Currency Translation Adjustment
AdjustmentToAccumulatedOtherComprehensiveGainLossForeignCurrencyTranslationAdjustment
6000
CY2023Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
28309000
CY2023Q3 gern Issuance Of Common Stock In Connection With Warrant Exercise Value
IssuanceOfCommonStockInConnectionWithWarrantExerciseValue
440000
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1044000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7204000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
290614000
us-gaap Profit Loss
ProfitLoss
-149220000
us-gaap Profit Loss
ProfitLoss
-132154000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
404000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
328000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
7281000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
8335000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1894000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
742000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
122000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
650000
us-gaap Share Based Compensation
ShareBasedCompensation
24392000
us-gaap Share Based Compensation
ShareBasedCompensation
14110000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
501000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
464000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
20283000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
28007000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1842000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
13694000
us-gaap Increase Decrease In Operating Liabilities
IncreaseDecreaseInOperatingLiabilities
4647000
us-gaap Increase Decrease In Operating Liabilities
IncreaseDecreaseInOperatingLiabilities
11084000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-174673000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-126805000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
821000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
766000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
292141000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
459727000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
290469000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
232602000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2493000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-227891000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
26696000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
9492000
gern Proceeds From Public Offering Issuance Of Common Stock And Warrants
ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants
140729000
gern Proceeds From Public Offering Issuance Of Common Stock And Warrants
ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants
213337000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
418000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
105912000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
366000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
168209000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
328741000
gern Effect Of Unrealized Losses And Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
17000
gern Effect Of Unrealized Losses And Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-9000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8940000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-25964000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
71138000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
57209000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
62198000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
31245000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to accrued liabilities, revenue recognition, fair value of marketable securities, operating leases, right-of-use assets, lease liabilities, income taxes, and stock-based compensation. We base our estimates on historical experience and on various other market specific and relevant assumptions that we believe to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p>
CY2024Q3 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P4Y
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6890000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7204000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
24392000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14110000
CY2024Q3 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
300000
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
400000
CY2024Q3 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
5871000
CY2024Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
13544000
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
868000
CY2024Q3 us-gaap Inventory Net
InventoryNet
20283000
CY2024Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
36824000
CY2024Q3 gern Cash And Cash Equivalents Unrealized Gains
CashAndCashEquivalentsUnrealizedGains
2000
CY2024Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
36826000
CY2024Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1854000
CY2024Q3 us-gaap Restricted Investments At Fair Value
RestrictedInvestmentsAtFairValue
1854000
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
315736000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1010000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
316742000
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
16815000
CY2023Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
16815000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1115000
CY2023Q4 us-gaap Restricted Investments At Fair Value
RestrictedInvestmentsAtFairValue
1115000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
306784000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
402000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
212000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
306974000
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
12842000
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
2000
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
1986000
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
2000
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
14828000
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
4000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
166518000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
211000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
166518000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
211000
CY2024Q3 gern Accrued Clinical Research Organizations And Clinical Trial Costs Current
AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent
19392000
CY2023Q4 gern Accrued Clinical Research Organizations And Clinical Trial Costs Current
AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent
23541000
CY2024Q3 gern Accrued Manufacturing Activities Current
AccruedManufacturingActivitiesCurrent
12326000
CY2023Q4 gern Accrued Manufacturing Activities Current
AccruedManufacturingActivitiesCurrent
14629000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
751000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
556000
CY2024Q3 us-gaap Interest Payable Current
InterestPayableCurrent
853000
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
768000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3167000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
814000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
36489000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
40308000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
2548000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
89955000
CY2024Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
92503000
CY2024Q3 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
7263000
CY2024Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
258000
CY2024Q3 gern Debt Instrument Unaccrued End Of Term Charge
DebtInstrumentUnaccruedEndOfTermCharge
1145000
CY2024Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
71562000
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
12275000
gern Number Of Severance Plan
NumberOfSeverancePlan
2
gern Loss Contingency Triggering Event Employee Termination Without Cause Following Change Of Control Period
LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod
P12M
gern Loss Contingency Triggering Event Period Following Change Of Control During Which No Comparable Employment Is Offered By Entity
LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity
P30D
gern Loss Contingency Triggering Event Period Following Change Of Control Within Which Employee Resigns Due To Material Change In Terms Of Employment
LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment
P12M
CY2024Q3 us-gaap Recorded Unconditional Purchase Obligation
RecordedUnconditionalPurchaseObligation
62400000

Files In Submission

Name View Source Status
0000950170-24-123282-index-headers.html Edgar Link pending
0000950170-24-123282-index.html Edgar Link pending
0000950170-24-123282.txt Edgar Link pending
0000950170-24-123282-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
gern-20240930.htm Edgar Link pending
gern-20240930.xsd Edgar Link pending
gern-ex10_1.htm Edgar Link pending
gern-ex31_1.htm Edgar Link pending
gern-ex31_2.htm Edgar Link pending
gern-ex32_1.htm Edgar Link pending
gern-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
gern-20240930_htm.xml Edgar Link completed
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable